AR062222A1 - Derivados del acido (3- amino-1,2,3,4- tetrahidro-9h- carbazol-9-il)- acetico - Google Patents
Derivados del acido (3- amino-1,2,3,4- tetrahidro-9h- carbazol-9-il)- aceticoInfo
- Publication number
- AR062222A1 AR062222A1 ARP070103462A ARP070103462A AR062222A1 AR 062222 A1 AR062222 A1 AR 062222A1 AR P070103462 A ARP070103462 A AR P070103462A AR P070103462 A ARP070103462 A AR P070103462A AR 062222 A1 AR062222 A1 AR 062222A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- alkyl
- alkylcarbonyl
- disubstituted
- halogen
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 2
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 2
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 abstract 2
- 125000005100 aryl amino carbonyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 abstract 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 abstract 1
- 102000015433 Prostaglandin Receptors Human genes 0.000 abstract 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000004670 alkyl amino thio carbonyl group Chemical group 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 abstract 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 abstract 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000001326 naphthylalkyl group Chemical group 0.000 abstract 1
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Su uso como moduladores del receptor de prostaglandina, muy particularmente como moduladores del receptor de prostaglandina D2, en el tratamiento de diversas enfermedades y trastornos mediados por las prostaglandinas, con composiciones farmacéuticas que contienen estos compuestos y con procesos para su preparacion. Reivindicacion 1: Un compuesto de la formula 1 en la cual R1, R2, R3 y R4 representan independientemente hidrogeno, alquilo C1-5, alcoxi C1-5, alquenilo (especialmente alilo o vinilo), halogeno, nitro, ciano, haloalcoxi C1-6, haloalquilo C1-6, alquilsulfonilo C1-6 o formilo; R5 representa hidrogeno, alquenilo, alquilo C1-6, cicloalquilalquilo C1-4, alcoxi C1-3-alquilo C1-4, aril-alquilo C1-4- o ariloxialquilo C1-4; donde arilo está no sustituido, mono- o disustituido con un grupo independientemente seleccionado entre alquilendioxi C1-2, alcoxi C1-4, alquilo C1-4, halogeno, trifluorometilo y trifluorometoxi; y R6 representa alquilaminocarbonilo C1-9, alquilaminotiocarbonilo C1-9, alquilcarbonilo C1-9, alcoxicarbonilo C1-9, arilalquenilcarbonilo; arilaminocarbonilo; arilaminotiocarbonilo; aril-alcoxi-C1-3-alcoxicarbonilo C1-3, arilalcoxicarbonilo C1-3, aril-alquilaminocarbonilo C1-3, arilalquilcarbonilo C1-6, arilalcoxi C1-3-alquilcarbonilo C1-3; alquilcarbonilo C1-3; arilcarbonilo; arilcarbonil-alquilcarbonilo C1-4, ariloxialquilcarbonilo C1-3 arilsulfonilaminocarbonilo; cicloalquil-alquilcarbonilo C1-3; diaril-alquilcarbonilo C1-3, heterociclilcarbonilo; heteroaril-alquilcarbonilo C1-3; heteroarilcarbonilo; aril-cicloalquilcarbonilo C3-6; cicloalquilcarbonilo o R7-alquilcarbonilo C1-4, donde el grupo alquilo C1-4 conector puede estar además monosustituido con arilo o disustituido con hidroxi y R7 representa arilaminocarbonilo, heteroarilaminocarbonilo, alquilaminocarbonilo C1-6, o arilalquilaminocarbonilo C1-3; donde arilo está no sustituido, mono- o disustituido con un grupo independientemente seleccionado entre alquilendioxi C1-2; alcoxi C1-6, alquilo C1-6, alquilsulfonilo C1-6; fenilo que está no sustituido, mono- o disustituido con sustituyentes independientemente seleccionados entre halogeno, trifluorometilo, metoxi y metilo; naftilo; fenilalquilo C1-3, donde el grupo fenilo está no sustituido, mono- o disustituido con sustituyentes independientemente seleccionados entre halogeno, trifluorometilo, metoxi y metilo; naftilalquilo C1-3; fenoxi, donde el grupo fenilo está no sustituido, mono- o disustituido con sustituyentes independientemente seleccionados entre halogeno, trifluorometilo, metoxi y metilo; naftiloxi; halogeno; hidroxi; haloalquilo C1-6, haloalcoxi C1-6, alquiltio C1-6 y alcoxicarbonilamino C1-4, o una sal de dicho compuesto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2006052723 | 2006-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062222A1 true AR062222A1 (es) | 2008-10-22 |
Family
ID=38805811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103462A AR062222A1 (es) | 2006-08-07 | 2007-08-06 | Derivados del acido (3- amino-1,2,3,4- tetrahidro-9h- carbazol-9-il)- acetico |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8143304B2 (es) |
| EP (2) | EP2316824A1 (es) |
| JP (1) | JP5220013B2 (es) |
| KR (1) | KR101411820B1 (es) |
| CN (1) | CN101500996B (es) |
| AR (1) | AR062222A1 (es) |
| AT (1) | ATE530523T1 (es) |
| AU (1) | AU2007282949B8 (es) |
| BR (1) | BRPI0715179A2 (es) |
| CA (1) | CA2658986C (es) |
| CL (1) | CL2007002274A1 (es) |
| CY (1) | CY1112276T1 (es) |
| DK (1) | DK2051962T3 (es) |
| ES (1) | ES2374321T3 (es) |
| HK (1) | HK1130062A1 (es) |
| HR (1) | HRP20120044T1 (es) |
| IL (1) | IL196891A (es) |
| MA (1) | MA30696B1 (es) |
| MX (1) | MX2009001105A (es) |
| MY (1) | MY147588A (es) |
| NO (1) | NO20090979L (es) |
| NZ (1) | NZ574705A (es) |
| PL (1) | PL2051962T3 (es) |
| PT (1) | PT2051962E (es) |
| RU (1) | RU2448092C2 (es) |
| SI (1) | SI2051962T1 (es) |
| TW (1) | TWI408126B (es) |
| WO (1) | WO2008017989A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005229356B2 (en) | 2004-03-11 | 2011-06-09 | Idorsia Pharmaceuticals Ltd | Tetrahydropyridoindole derivatives |
| WO2006070325A2 (en) | 2004-12-27 | 2006-07-06 | Actelion Pharmaceuticals Ltd | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists |
| US8067445B2 (en) | 2008-02-01 | 2011-11-29 | Panmira Pharmaceuticals, Llc | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
| WO2009108720A2 (en) | 2008-02-25 | 2009-09-03 | Amira Pharmaceuticals, Inc. | Antagonists of prostaglandin d2 receptors |
| US8501959B2 (en) * | 2008-06-24 | 2013-08-06 | Panmira Pharmaceuticals, Llc | Cycloalkane[B]indole antagonists of prostaglandin D2 receptors |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
| GB2465062B (en) * | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| PL2401269T3 (pl) | 2009-02-24 | 2014-07-31 | Merck Sharp & Dohme | Pochodne indolu jako antagoniści receptora CRTH2 |
| KR20120038544A (ko) | 2009-07-31 | 2012-04-23 | 판미라 파마슈티칼스, 엘엘씨 | Ｄｐ2 수용체 길항제의 안과용 약학 조성물 |
| JP2013501052A (ja) | 2009-08-05 | 2013-01-10 | パンミラ ファーマシューティカルズ，エルエルシー． | Ｄｐ２アンタゴニストおよびその用途 |
| ES2524079T3 (es) | 2010-03-22 | 2014-12-04 | Actelion Pharmaceuticals Ltd. | Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9H-carbazol y su uso como moduladores del receptor de prostaglandina D2 |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| MX338516B (es) * | 2011-04-14 | 2016-04-20 | Actelion Pharmaceuticals Ltd | Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina. |
| PT3119779T (pt) | 2014-03-17 | 2018-10-19 | Idorsia Pharmaceuticals Ltd | Derivados de ácido azaindol acético e sua utilização como modeladores de recetor d2 de prostaglandina |
| MX2016011900A (es) | 2014-03-18 | 2016-12-05 | Actelion Pharmaceuticals Ltd | Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2. |
| CN104402798B (zh) * | 2014-10-21 | 2016-09-14 | 杭州瑞德化工有限公司 | 一种3-氨基-1，2，3，4-四氢咔唑的拆分方法 |
| US10351558B2 (en) | 2015-02-16 | 2019-07-16 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| EP3350179B1 (en) | 2015-09-15 | 2021-01-13 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
| CN112094223B (zh) * | 2019-06-18 | 2023-09-15 | 华东师范大学 | 一类脲基四氢咔唑类小分子有机化合物及用途 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4808608A (en) * | 1986-01-23 | 1989-02-28 | Merck & Co., Inc. | Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use |
| US4988820A (en) * | 1986-02-21 | 1991-01-29 | Bayer Aktiengesellschaft | Cycloalkano(1,2-B) indole-sulponamides |
| DE3631824A1 (de) * | 1986-02-21 | 1988-03-31 | Bayer Ag | Cycloalkano(1.2-b)indol-sulfonamide |
| US5298626A (en) * | 1991-01-18 | 1994-03-29 | Hoechst-Roussel Pharmaceuticals Incorporated | Select cyclopent[b]indoles |
| GB9113802D0 (en) * | 1991-06-26 | 1991-08-14 | Smithkline Beecham Plc | Medicaments |
| US5350762A (en) * | 1993-03-08 | 1994-09-27 | Hoechst-Roussel Pharmaceuticals Incorporated | Tetrahydrocyclopent[B]indole methanamines and related compounds |
| US6713473B1 (en) * | 1999-04-20 | 2004-03-30 | Meiji Seika Kaisha, Ltd. | Tricyclic compounds |
| US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
| ATE340796T1 (de) | 2001-05-23 | 2006-10-15 | Merck Frosst Canada Inc | Dihydropyrrolo(1,2-aöindol- und tetrahydropyrido)1,2-aöindolderivate als prostaglandin rezeptor antagonisten |
| GB2408001B (en) | 2001-10-18 | 2006-03-29 | Derek Colin Tolley | Filtration of liquid media |
| CA2468880A1 (en) * | 2001-12-14 | 2003-06-26 | Zentaris Gmbh | Tetrahydrocarbazole derivatives as ligands for g-protein coupled receptors (gpcr) |
| AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| WO2003097598A1 (fr) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Composé comprenant un antagonisme du récepteur de pdg2 |
| WO2003097042A1 (fr) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Antagoniste de recepteur de pdg2 |
| GB2388540A (en) * | 2002-05-17 | 2003-11-19 | Bayer Ag | New use of Ramatroban |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| WO2004039807A1 (en) | 2002-10-30 | 2004-05-13 | Merck Frosst Canada & Co. | Pyridopyrrolizine and pyridoindolizine derivatives |
| EP1600440A1 (en) | 2003-03-06 | 2005-11-30 | Ono Pharmaceutical Co., Ltd. | Indole derivative compounds and drugs containing the compounds as the active ingredient |
| WO2004103970A1 (en) | 2003-05-20 | 2004-12-02 | Merck Frosst Canada Ltd. | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists |
| SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| JP2006527205A (ja) | 2003-06-12 | 2006-11-30 | メルク フロスト カナダ リミテツド | Ｄｐ受容体拮抗物質としてのシクロアルカンピロロピリジン |
| SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| WO2005033099A2 (en) | 2003-10-03 | 2005-04-14 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
| US20070232681A1 (en) | 2003-10-14 | 2007-10-04 | Oxagen Limited | Compounds Having Crth2 Antagonist Activity |
| WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| GB2407318A (en) | 2003-10-23 | 2005-04-27 | Oxagen Ltd | Substituted Indol-3-yl acetic acid derivatives |
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| US7019022B2 (en) | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| RU2373208C2 (ru) | 2004-01-31 | 2009-11-20 | Актимис Фармасьютикалз, Инк. | Производные имидазо[1,2-c]пиримидинилуксусной кислоты |
| WO2005094816A1 (en) | 2004-03-11 | 2005-10-13 | Actelion Pharmaceuticals Ltd | Indol-1-yl-acetic acid derivatives |
| AU2005229356B2 (en) * | 2004-03-11 | 2011-06-09 | Idorsia Pharmaceuticals Ltd | Tetrahydropyridoindole derivatives |
| US20050234030A1 (en) | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
| GB0412914D0 (en) | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
| MY144903A (en) | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
| BRPI0514611A (pt) | 2004-08-26 | 2008-06-17 | Actelion Pharmaceuticals Ltd | uso de um composto, compostos, e, medicamento |
| US7732618B2 (en) | 2004-09-21 | 2010-06-08 | Wyeth | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof |
| JP2008513512A (ja) * | 2004-09-21 | 2008-05-01 | アサーシス， インク． | Ｃｒｔｈ２受容体拮抗作用を示すインドール酢酸およびこれらの使用 |
| WO2006070325A2 (en) | 2004-12-27 | 2006-07-06 | Actelion Pharmaceuticals Ltd | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists |
| DOP2006000016A (es) | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
| GB2422829A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
| GB2422830A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
| GB2422831A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
| NZ560513A (en) | 2005-02-25 | 2010-07-30 | Ono Pharmaceutical Co | Indole compound and use thereof |
| GB0504150D0 (en) | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
| GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| PT1891075E (pt) | 2005-05-24 | 2011-11-10 | Merck Serono Sa | Derivados espiro tricíclicos como moduladores do crth2 |
| GB0512944D0 (en) | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Indolizine compounds |
| EP1916245B1 (en) | 2005-07-22 | 2011-10-26 | Shionogi & Co., Ltd. | Indole derivative having pgd2 receptor antagonist activity |
| JP5064219B2 (ja) | 2005-07-22 | 2012-10-31 | 塩野義製薬株式会社 | Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体 |
| JP4972644B2 (ja) | 2005-08-12 | 2012-07-11 | メルク カナダ インコーポレイテッド | Ｃｒｔｈ２受容体拮抗薬としてのインドール誘導体 |
| WO2007022501A2 (en) | 2005-08-18 | 2007-02-22 | Microbia, Inc. | Useful indole compounds |
| US8143285B2 (en) | 2005-09-06 | 2012-03-27 | Shionogi & Co., Ltd. | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity |
| GB0518783D0 (en) | 2005-09-14 | 2005-10-26 | Argenta Discovery Ltd | Indolizine compounds |
| GB0521275D0 (en) | 2005-10-19 | 2005-11-30 | Argenta Discovery Ltd | 3-Aminoindole compounds |
| GB0525144D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525143D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525141D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525337D0 (en) | 2005-12-13 | 2006-01-18 | Novartis Ag | Organic compounds |
-
2007
- 2007-08-02 EP EP11000641A patent/EP2316824A1/en not_active Withdrawn
- 2007-08-02 CN CN2007800292169A patent/CN101500996B/zh not_active Expired - Fee Related
- 2007-08-02 JP JP2009523396A patent/JP5220013B2/ja not_active Expired - Fee Related
- 2007-08-02 ES ES07805287T patent/ES2374321T3/es active Active
- 2007-08-02 AU AU2007282949A patent/AU2007282949B8/en not_active Ceased
- 2007-08-02 EP EP07805287A patent/EP2051962B1/en active Active
- 2007-08-02 SI SI200730818T patent/SI2051962T1/sl unknown
- 2007-08-02 MY MYPI20090462A patent/MY147588A/en unknown
- 2007-08-02 CA CA2658986A patent/CA2658986C/en not_active Expired - Fee Related
- 2007-08-02 PL PL07805287T patent/PL2051962T3/pl unknown
- 2007-08-02 NZ NZ574705A patent/NZ574705A/en not_active IP Right Cessation
- 2007-08-02 KR KR1020097004370A patent/KR101411820B1/ko not_active Expired - Fee Related
- 2007-08-02 MX MX2009001105A patent/MX2009001105A/es active IP Right Grant
- 2007-08-02 AT AT07805287T patent/ATE530523T1/de active
- 2007-08-02 WO PCT/IB2007/053046 patent/WO2008017989A1/en active Application Filing
- 2007-08-02 BR BRPI0715179-9A patent/BRPI0715179A2/pt not_active IP Right Cessation
- 2007-08-02 US US12/376,932 patent/US8143304B2/en not_active Expired - Fee Related
- 2007-08-02 RU RU2009107889/04A patent/RU2448092C2/ru not_active IP Right Cessation
- 2007-08-02 DK DK07805287.5T patent/DK2051962T3/da active
- 2007-08-02 PT PT07805287T patent/PT2051962E/pt unknown
- 2007-08-06 CL CL200702274A patent/CL2007002274A1/es unknown
- 2007-08-06 AR ARP070103462A patent/AR062222A1/es unknown
- 2007-08-06 TW TW096128871A patent/TWI408126B/zh not_active IP Right Cessation
-
2009
- 2009-02-04 IL IL196891A patent/IL196891A/en not_active IP Right Cessation
- 2009-02-17 MA MA31646A patent/MA30696B1/fr unknown
- 2009-03-04 NO NO20090979A patent/NO20090979L/no not_active Application Discontinuation
- 2009-10-28 HK HK09110028.6A patent/HK1130062A1/xx not_active IP Right Cessation
-
2012
- 2012-01-13 HR HR20120044T patent/HRP20120044T1/hr unknown
- 2012-01-25 CY CY20121100090T patent/CY1112276T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062222A1 (es) | Derivados del acido (3- amino-1,2,3,4- tetrahidro-9h- carbazol-9-il)- acetico | |
| CR10346A (es) | Derivados de azabiciclo[3.1.0]hexil como modulares de los receptores de dopamina d3 | |
| AR055779A1 (es) | Proceso de preparacion de azoxistrobina y composicion que contiene al compuesto | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| AR085903A1 (es) | Compuestos de pirazol sustituidos con halogeno | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| AR060489A1 (es) | Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol | |
| AR069798A1 (es) | Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa. | |
| AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
| EA200600317A1 (ru) | Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты) | |
| PA8828201A1 (es) | Compuestos triazina como inhibidores mtor y quinasa p13 | |
| RU2005110918A (ru) | Органические соединения | |
| UY31525A1 (es) | Derivados de aminobenzamida con agentes utiles para controlar parasitos animales | |
| PE20161035A1 (es) | Compuestos y usos de estos para la modulacion de la hemoglobina | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR073932A1 (es) | Compuestos de esteres de acido 2-(aminometiliden)-4,4-difluoro-3- oxobutirico y procedimiento para su preparacion | |
| JP2014513051A5 (es) | ||
| EA200801608A1 (ru) | Производные бензимидазолонкарбоновой кислоты | |
| JP2017519802A5 (es) | ||
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| AR053345A1 (es) | Compuesto de 1,2,4 triazolo-5-ona como inhibidores de la transcriptasa inversa | |
| AR062082A1 (es) | Derivados de piridazina con actividad microbicida | |
| AR062192A1 (es) | Proceso para preparar amidrazonas | |
| AR077472A1 (es) | Inhibidores de transportador de glicina | |
| AR085909A1 (es) | Derivados de azaespirodecanona, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos para el tratamiento de diabetes, obesidad y enfermedades cardiovasculares, entre otras |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |